TG Therapeutics

October 19, 2017October 20, 2017

#MSParis2017 – TG Therapeutics’ Ublituximab Depletes Harmful B-cells and Lowers MRI Lesions, Trial Shows

News

TG Therapeutics’ ublituximab nearly eradicated a type of immune B-cell believed to be involved in multiple sclerosis, according to a Phase 2 clinical trial. The result was that none ... Read more

October 3, 2017October 4, 2017

MS Society, TG Therapeutics Partner to Advance Potential Oral Therapy for Progressive MS

News

Fast Forward, a non-profit subsidiary of the National Multiple Sclerosis Society, will give financial support to TG Therapeutics to advance TGR-1202 (umbralisib) into preclinical testing as a ... Read more

September 19, 2017September 19, 2017

TG Therapeutics Recruiting Patients for Two Phase 3 Trials of Relapsing MS Therapy TG-1101

News

TG Therapeutics is recruiting participants for two Phase 3 clinical trials that will evaluate the safety and effectiveness of TG-1101 (ublituximab) as a treatment for relapsing forms of ... Read more

September 5, 2017September 6, 2017

#MSParis2017 – TG Therapeutics to Discuss Ublituximab’s Effectiveness at ECTRIMS–ACTRIMS Meeting in Paris

News

TG Therapeutics will discuss ublituximab’s ability to deplete B-cells linked to multiple sclerosis and to reduce inflammatory brain lesions at the 7th Joint ECTRIMS–ACTRIMS Meeting in ... Read more

August 8, 2017August 8, 2017

TG Therapeutics, FDA Agree on Phase 3 Program to Evaluate Relapsing MS Therapy TG-1101

News

TG Therapeutics and the U.S. Food and Drug Administration (FDA) have agreed on a special protocol assessment for a Phase 3 trial program evaluating TG-1101 (ublituximab) to potentially ... Read more

June 28, 2017June 28, 2017

In Ongoing Phase 2 Trial, Ublituximab Seen to Effectively and Safely Deplete B-cells

News

TG Therapeutics’ investigational treatment — ublituximab (TG-1101) — led to a near total depletion of B-cells in patients with relapsing forms of multiple sclerosis (MS) taking part in an ongoing ... Read more

January 12, 2017January 13, 2017

TG Therapeutics’ B-cell Therapy Could Allow for Rapid Dosing, Early Data Suggest

News

Early data from TG Therapeutics’ Phase 2 trial of its B-cell-targeting experimental multiple sclerosis (MS) treatment ublituximab (TG-1101), showed that the drug is well-tolerated and effectively reduces B-cells ... Read more

August 30, 2016August 30, 2016

TG Therapeutics’ Potential Neuromyelitis Optica Treatment Named Orphan Drug by FDA

News

The U.S. Food and Drug Administration (FDA) has designated TG-1101 (ublituximab), a glycoengineered anti-CD20 monoclonal antibody by TG Therapeutics, an orphan drug to advance its development. The drug is a potential treatment for neuromyelitis ... Read more

May 5, 2016May 5, 2016

New Phase 2 Trial of a B-cell Antibody, TG-1101, to Treat Relapsing MS Getting Underway

News

TG Therapeutics recently announced the opening of a new clinical trial evaluating TG-1101, its glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing-remitting multiple sclerosis (RRMS). The Phase 2 ... Read more

Pin It on Pinterest